Brentuximab vedotin combined with cyclophosphamide, doxorubicin, and prednisone (CHP) shows promising results as a first-line ...

Vermeland developed breast implant-associated anaplastic large cell lymphoma (BIA-ALCL), a type of cancer not yet well understood, after undergoing mastectomy and reconstruction due to breast cancer.

Convergent Mutations and Kinase Fusions Lead to Oncogenic STAT3 Activation in Anaplastic Large Cell Lymphoma. Cancer Cell , 2015; 27 (4): 516 DOI: 10.1016/j.ccell.2015.03.006 Cite This Page : ...

Anaplastic large cell lymphoma ... Together, these efforts are instrumental in constructing a more comprehensive treatment framework that marries targeted therapy with precision diagnostics.

A general problem encountered in cancer therapy is that many patients develop resistance to a drug over the course of treatment. In the case of the blood cancer Anaplastic Large Cell Lymphoma ...

Breast implant-associated anaplastic large-cell lymphoma (BIA-ALCL) is a rare, breast implant–associated T-cell lymphoma in which CD30 is expressed and anaplastic lymphoma kinase (ALK) expression is ...

PURPOSETo analyze the efficacy of a risk-stratified treatment of children with relapsed anaplastic large cell lymphoma (ALCL). The ALCL-Relapse trial (ClinicalTrials.gov identifier: NCT00317408) ...

Prutsch, N., et al. (2024) STAT3 couples activated tyrosine kinase signaling to the oncogenic core transcriptional regulatory circuitry of anaplastic large cell lymphoma. Cell Reports Medicine ...

From 2020 to 2022, the investigators treated 15 adults with ALK-positive ALCL with off-label brigatinib at a dozen centers in the French Lymphoma Study Association.

Adcetris is also indicated as monotherapy or in combination with chemotherapy for the treatment of certain types of classical Hodgkin lymphoma, anaplastic large cell lymphoma and peripheral T ...